Key Takeaways
- Growth accelerates, guidance set: Constant-currency revenue grew 4.2% QoQ, the second consecutive quarter of industry-leading growth, and FY25 guidance calls for 10–13% CC growth net of a residual offshore shift in the top account.
- Deal wins hit a record: FY24 delivered the highest ever net new ACV wins in a single year, with at least one large deal win in each of the last three quarters, and new logo deal sizes over 60% higher than the prior year.
- Margin expansion is a medium-term story: FY25 EBIT margin is guided to 11–12% as investments are front-loaded; management targets 50–75 bps of annual expansion thereafter, with the payoff beginning in 12–18 months.
- QBSS acquisition fills a gap: The $39.2 mn buyout adds mid/back-office revenue cycle capabilities and entry into the physician billing market, and is expected to be margin- and EPS-accretive.
- What to watch next quarter: Whether the seasonal moderation in card-issuer collections is truly marginal, the pace of QBSS integration, and any early signs that the front-loaded investment phase is converting pipeline into revenue.
Growth & Demand Environment
- Broad-based acceleration: All four verticals and both major geographies grew QoQ in constant currency, with CMT up 8%, Diverse up 7%, and Healthcare up 3%. The US and Europe each grew 4% QoQ.
- Second-half rebound: After a flat first half, growth accelerated in H2, delivering full-year CC growth of 1.1% within the guided range. Management expects the momentum to sustain into FY25 given the record deal pipeline.
- Offshore shift creates optical headwinds: An ongoing onshore-to-offshore transition in the top client suppresses reported revenue even as additional business is won; this residual drag is baked into the FY25 growth guidance.
- UK cost pressures are a tailwind: Rising national minimum wages and an economic slowdown are pushing UK companies toward offshoring and outsourcing, a structural demand driver that management expects to continue.
- Sales capacity expanded: The sales team grew by a third over the last six months, and dedicated client partners have been assigned to a defined set of accounts, signaling a bet that the pipeline can convert.
Idnani: "Our scale is just right to gain from the discontinuities caused by the macro shifts. As our clients move from a growth playbook to a growth and efficiency playbook, they are looking for a partner who has a deep understanding of their operating environment, has the ability to bring technology and operations together to deliver business outcomes and has the scale to execute effectively and efficiently. We pick all the three boxes."
Vertical Performance
| Vertical | Trend | Commentary |
|---|---|---|
| CMT | ▲ Strong | Up 8% QoQ CC; growth broadened beyond the top client, with EdTech scaling and Consumer Tech expanding its footprint. |
| Diverse | ▲ Strong | Up 7% QoQ CC and nearly 50% YoY, driven by utilities and energy demand. |
| Healthcare | ▲ Solid | Up 3% QoQ CC; a cyber-attack at a clearinghouse temporarily hit provider volumes, but the payer segment more than offset it, with ACV wins jumping 60% in FY24. |
| BFS | ▬ Mixed | Up 1.7% QoQ CC but down 3.3% YoY on a mortgage base effect; elevated rates remain an overhang, while rising card delinquencies are driving collection volumes. |
- Mortgage segment being weather-proofed: The business is largely stable, and efforts are underway to diversify beyond mono-line lenders into mid-tier and regional banks, expand into servicing and HELOCs, and add real estate adjacencies. Quarterly aberrations are possible but the long-term structure is being rebuilt.
- Payer segment momentum: The US healthcare payer market is in transition post-pandemic, and Firstsource is seeing substantial interest in GenAI solutions, with provider-side GenAI involvement expected to increase in coming quarters.
Deal Wins & Order Book
- Record ACV year: FY24 net new ACV wins were the highest ever, with at least one large deal closed in each of the last three quarters. 41 new clients were added in FY24, 9 of them in Q4.
- Top-5 bank transformational deal: One of the largest deal wins in the last five years came from a top-five US bank expanding the relationship with a large transformational program.
- Top client renewed for a decade: The contract with the largest client was extended as primary outsourcing partner for another 10 years, locking in the revenue base.
- New logo quality rising: New logo deal sizes were over 60% higher than last year, and wins spanned a large UK cooperative financial institution, a top-ranked US hospital, and a major US healthcare delivery system player.
- Proactive proposals winning: Clients are responding to proposals that address cost optimization, process transformation, and revenue growth simultaneously, and Firstsource's position as a challenger brand with deep domain and end-to-end tech capabilities is yielding results.
QBSS Acquisition
- Deal structure: $39.2 mn total consideration, split into $25.9 mn upfront, $5.6 mn deferred, and $7.8 mn tied to milestones over two years. Funded entirely through internal accruals.
- What it brings: QBSS generated $14.6 mn in FY24 revenue, growing at a 23% CAGR over two years. It adds roughly 1,800 offshore employees and capabilities in medical coding, denial management, AR follow-up, and clinical documentation improvement.
- Strategic logic: The acquisition opens the physician billing market, which Firstsource did not previously serve, and creates an end-to-end revenue cycle management proposition spanning hospitals, physician practices, and large integrated health systems. Management expects the combination to capture the next wave of technology- and AI-led RCM outsourcing.
- Financial impact: Expected to be margin- and EPS-accretive; integration is planned during the current quarter. Amortization charges from the purchase price allocation are not yet quantified.
Idnani: "The combination will give us an unmatched ability to offer lower cost, technology led, higher efficiency, end to end, revenue cycle management services for hospitals, physician practices and large integrated health systems. This will also allow us to capture the next wave of outsourcing of revenue cycle management, which is going to be technology and AI led and disrupt other traditional people-based RCM players in the marketplace."
Margins & Investment Phase
| Margin walk (QoQ) | Impact |
|---|---|
| Normalization of Q3 compensation hike and promotion drag | +30 bps |
| Q4 FY24 EBIT margin → 11.0% | Up from 10.7% |
- FY24 within the band: Full-year EBIT margin landed at 11.1%, inside the 11–11.5% guided range, and up 160 bps YoY.
- FY25 margin guided to 11–12%: The range embeds upfront investments in sales, account management, capabilities, and brand, funded mainly through internal cost optimizations. Quarterly puts and takes may cause variation, but management expects the full-year outcome to stay in a narrow band.
- Cost levers already pulled: Span of control improved by a factor of two over the last six months, the global payroll system was consolidated offshore, and employee shared services were centralized. The savings are being recycled into growth investments rather than dropped to the bottom line.
- Medium-term expansion path: Management targets 50–75 bps of annual EBIT margin expansion over a 3–4 year horizon, with the payoff beginning in the next 12–18 months. The investment phase is described as "front-loaded," but no specific end-quarter is committed.
Idnani: "I am very confident about improving our margin trajectory over the medium term, without compromising on our growth aspirations or the investment plans."
People & Operating Model
- Headcount surge: 1,993 colleagues added in Q4, bringing the total to 27,940. Two-thirds of the gross addition over the last three quarters was offshore, and the offshore contribution rose nearly 6 percentage points in that period.
- Attrition trending down: Offshore attrition fell to 30.8% (from 33.8% in Q3), and onsite attrition dropped to 42.5% (from 43.3%). Trailing-twelve-month attrition saw a double-digit reduction, and early attrition dropped over 40% in Q4, driven by engagement programs, internal mobility (over 750 internal moves), and streamlined onboarding.
- Offshore shift as a structural lever: Management expects the offshore contribution to keep rising, which supports both margin expansion and the ability to offer cost-competitive propositions. The local footprint in the US and UK is retained as a competitive differentiator for culturally sensitive client relationships.
- Philippines scaling up: An additional facility has been taken to support deal wins and pipeline in the Philippine market, and the footprint is expected to continue growing.
- Senior hires signal ambition: Hasit Trivedi joined as Chief Digital & AI Officer, Akash Pugalia was hired to lead Trust & Safety services, and Aniket Maindarkar came in earlier in the year to strengthen analyst and advisor relationships.
CX Market Opportunity
- Underpenetrated TAM: Management estimates that nearly two-thirds of the CX market is still in-sourced, creating a long runway for outsourcing and offshoring penetration to increase over the next 3–5 years, albeit in non-linear fashion.
- Dual share-gain opportunity: Firstsource sees itself taking share from both large pure-play CX players, where clients face concentration risk, and from the long tail of smaller, undifferentiated providers. The combination of end-to-end capabilities, deep vertical expertise, and a willingness to disrupt people-based models with technology is the stated differentiator.
Idnani: "Unlike our scale peers, we are not constrained to proactively leverage technology to disrupt existing people-based execution models. At the same time, we have the advantage of having end-to-end capabilities and a strong referral network of our clients... We today see the opportunity to benefit from taking share from both scale players as well as undifferentiated smaller players in the market by virtue of our position in the market."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY25 revenue growth | 10–13% constant currency, net of residual offshore shift in top account and including QBSS contribution | FY25 |
| FY25 EBIT margin | 11–12%, including upfront investments | FY25 |
| Medium-term margin expansion | 50–75 bps annual EBIT margin improvement, starting to play out in next 12–18 months | 3–4 year horizon |
| Organic revenue run-rate | US $1 billion exit revenue run-rate on an organic basis | By FY26 |
| QBSS integration | Integration planned during current quarter; margin- and EPS-accretive | Q1 FY25 |
| Offshore contribution | Expected to continue increasing | Ongoing |
| Philippines footprint | Expected to continue scaling up | Ongoing |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue | ₹1,670.5 cr, +7.3% YoY; $201 million, +6.2% YoY and +4.9% QoQ |
| Constant currency revenue growth | 4.5% YoY, following 2.8% in Q3; 4.2% QoQ |
| EBIT margin | 11%, down 60 bps YoY, up 30 bps QoQ from 10.7% |
| Operating profit | ₹183 cr, +1.7% over Q4 FY23 |
| Net profit | ₹133.5 cr, 8% of revenue |
| Diluted EPS | ₹1.9 |
| Tax rate | 16.2% |
| DSO | 62 days, stable QoQ |
| Net debt | ₹604.2 cr, vs ₹439.8 cr as of Dec 31, 2023 and ₹615.9 cr as of Mar 31, 2023 |
| Cash and investments | ₹208.1 cr, after dividend payout of ₹240.6 cr |
| Total employee count | 27,940 as of Mar 31, 2024; 1,993 added in Q4 |
| Trailing 12-month attrition (offshore) | 30.8%, vs 33.8% in Q3 and 42.3% in Q4 FY23 |
| Trailing 12-month attrition (onsite) | 42.5%, vs 43.3% in Q3 and 44.9% in Q4 FY23 |
| BFS vertical constant currency growth | +1.7% QoQ, -3.3% YoY |
| Healthcare vertical constant currency growth | +5% YoY, +3% QoQ |
| CMT vertical constant currency growth | +9% YoY, +8% QoQ |
| Diverse vertical constant currency growth | ~50% YoY, +7% QoQ |
| US constant currency growth | +4% QoQ; +1% YoY in FY24 |
| Europe constant currency growth | +4% QoQ; +5% YoY in FY24 |
| New logos added | 9 in Q4; 41 in FY24 |
| New logo deal sizes | Over 60% higher than last year |
| FY25 constant currency revenue growth guidance | 10% to 13%, net of residual offshore shift in top account and QBSS contribution |
| FY25 EBIT margin guidance | 11% to 12%, including upfront investments |
| Medium-term EBIT margin expansion target | 50 to 75 bps per year, post initial investment phase |
| Organic revenue run-rate target | $1 billion exit run-rate by FY26 |
| QBSS acquisition purchase consideration | $39.2 million: $25.9 million upfront, $5.6 million deferred, $7.8 million milestone-linked over 2 years |
| QBSS FY24 revenue | $14.6 million, CAGR of 23% over last two years |
| Q4 closing pipeline | Up 25% YoY |
| Offshore revenue share increase | Up by close to 6% over the last four quarters |
| Gross headcount addition offshore share | Two-thirds over the last three quarters |
| ROCE (FY24) | 15.4%, vs 13.4% in FY23 |
| Hedge book (GBP) | £6.72 cr coverage for next 12 months at average rate of ₹106 |
| Hedge book (USD) | $62.5 million coverage at average rate of ₹84.52 |